Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2025 May 5;6(3):191-202.
doi: 10.1158/2643-3230.BCD-24-0156.

High-Dose Methotrexate, Ibrutinib, and Temozolomide in the Treatment of Newly Diagnosed Primary CNS Lymphoma: A Multicenter, Prospective Phase II Study

Yan Gao #  1 , Liqin Ping #  1   2 , Changguo Shan #  3 , He Huang  1 , Zhiming Li  1 , Hui Zhou  4 , Mingyao Lai  3 , Linbo Cai  3 , Bing Bai  1 , Cheng Huang  1 , Haoqing Chen  1 , Xiaoyu Hong  5 , Xiaoxiao Wang  1 , Huiqiang Huang  1
Affiliations
Clinical Trial

High-Dose Methotrexate, Ibrutinib, and Temozolomide in the Treatment of Newly Diagnosed Primary CNS Lymphoma: A Multicenter, Prospective Phase II Study

Yan Gao et al. Blood Cancer Discov. .

Abstract

We report promising efficacy and good tolerability of Bruton tyrosine kinase (BTK) inhibitor ibrutinib in treatment of newly diagnosed PCNSL. Additionally, we explored the contribution of ctDNA profiling to predictive potential in this prospective study. The consistency of ctDNA clearance from CSF/plasma was associated with more sustained treatment response and survival.

PubMed Disclaimer

Conflict of interest statement

X. Hong reports other support from Nanjing Geneseeq Technology Inc. outside the submitted work. No disclosures were reported by the other authors.

Figures

Figure 1.
Figure 1.
PFS and OS by the Kaplan–Meier method. A, The 2-year PFS was 57.6% (95% CI, 49.0–66.2). B, The 2-year OS was 84.8% (95% CI, 78.6–91.0).
Figure 2.
Figure 2.
Swimmer plot of the best overall response assessed by investigators for the treatment duration for all patients.
Figure 3.
Figure 3.
Summary of clinical features and genomic alterations in samples of tumor tissue (A), CSF (B), and plasma (C) at baseline. “PD status” refers to whether disease progression occurred during induction therapy or consolidation therapy. PD, progressive disease; PR, partial response; SD, stable disease; SV, structural variant.
Figure 4.
Figure 4.
Dynamic monitoring of ctDNA in CSF and plasma during induction therapy and maintenance therapy. Nonresponders, patients who had stable disease or disease progression. Responders, patients who achieved a CR or partial response.
See this image and copyright information in PMC

References

    1. Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, et al. . The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol 2021;23:1231–51. - PMC - PubMed
    1. Campo E, Jaffe ES, Cook JR, Quintanilla-Martinez L, Swerdlow SH, Anderson KC, et al. . The international consensus classification of mature lymphoid neoplasms: a report from the clinical advisory committee. Blood 2022;140:1229–53. - PMC - PubMed
    1. Illerhaus G, Marks R, Ihorst G, Guttenberger R, Ostertag C, Derigs G, et al. . High-dose chemotherapy with autologous stem-cell transplantation and hyperfractionated radiotherapy as first-line treatment of primary CNS lymphoma. J Clin Oncol 2006;24:3865–70. - PubMed
    1. Miller DC, Hochberg FH, Harris NL, Gruber ML, Louis DN, Cohen H. Pathology with clinical correlations of primary central nervous system non-Hodgkin’s lymphoma. The Massachusetts General Hospital experience 1958-1989. Cancer 1994;74:1383–97. - PubMed
    1. Houillier C, Soussain C, Ghesquières H, Soubeyran P, Chinot O, Taillandier L, et al. . Management and outcome of primary CNS lymphoma in the modern era: an LOC network study. Neurology 2020;94:e1027–39. - PMC - PubMed

Publication types

MeSH terms